News

Friday 6th May 2016

Cumberland Readying a Phase 2 Trial of Oral Drug, Ifetroban, to Treat Scleroderma

Cumberland Pharmaceuticals, Inc., recently announced the addition to its drug pipeline of Vasculan (ifetroban), an oral capsule that soon will enter clinical testing as a treatment of systemic sclerosis (SSc), or scleroderma.

Friday 6th May 2016

Scleroderma and Raynaud's in the Uttoxeter Advertiser

Tuesday 26th April 2016

Drug-induced Raynaud’s phenomenon is ‘probably underestimated'

Raynaud's phenomenon can be triggered or worsened by certain drugs, such as beta blockers. But knowledge about the condition is limited.

Tuesday 26th April 2016

M10 Peptide Shows Anti-Fibrotic Activity in Mice

Researchers recently discovered a natural molecule, the M10 peptide, that can significantly decrease fibrosis in a mouse model of scleroderma.

Tuesday 19th April 2016

Largest scleroderma study to date has created a complete genetic map of the disease

Friday 15th April 2016

How I Manage My Auto Immune Diseases Without Medication

Well! It’s not easy but I have managed it with a few changes over the years to my nutrition and a good exercise plan.

Thursday 14th April 2016

What Exactly is 'Pre-Scleroderma'?

Tuesday 12th April 2016

Endothelin-1 Receptor Blockers Again Shown to Be Ineffective in Treating Skin Fibrosis

Saturday 2nd April 2016

What is research doing for me?

Prof. Denton, Consultant Rheumatologist at the Royal Free Hospital, London opened the World Systemic Sclerosis Congress with a presentation on 'What is research doing for me?' This uplifting and informative presentation highlighted the positive breakthroughs taking place in scleroderma research.

Wednesday 30th March 2016

Halfway Point Marked in Scleroderma Patient Enrolment for Cytori's ECCS-50 Phase 3 Trial

Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50 percent of target enrollment.